摘要
目的探讨贝伐珠单抗联合化疗对晚期肺癌患者血清肿瘤标志物及免疫功能的影响。方法将80例晚期肺癌患者根据不同治疗方式分为观察组及对照组,每组40例。对照组采用顺铂联合紫杉醇(TP)化疗,观察组在对照组基础上联合贝伐珠单抗治疗,比较两组患者血清肿瘤标志物水平、免疫功能指标水平、临床疗效及不良反应。结果治疗后,两组患者糖类抗原125(CA125)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、血清癌胚抗原(CEA)水平均明显低于本组治疗前,且观察组均明显低于对照组,差异均有统计学意义(P﹤0.01)。治疗后,两组患者免疫功能指标CD3^(+)、CD4^(+)、CD8^(+)水平均明显低于本组干预前,但观察组均明显高于对照组,差异均有统计学意义(P﹤0.01)。观察组患者疾病控制率为92.50%(37/40),高于对照组的72.50%(29/40),差异有统计学意义(χ^(2)=5.541,P=0.019)。两组患者不良反应发生率比较,差异均无统计学意义(P﹥0.05)。结论贝伐珠单抗联合TP化疗治疗晚期肺癌可有效降低血清肿瘤标志物水平,抑制疾病进展,同时控制化疗对机体免疫功能产生的影响,提升临床效果,应用价值较高。
Objective To explore the effect of bevacizumab combined chemotherapy on serum tumor markers and immunity function in patients with advanced lung cancer.Method A total of 80 patients with advanced lung cancer were divided into control group[n=40,cisplatin+paclitaxel(TP)]and observation group(n=40,TP+bevacizumab)according to different treatment methods.The levels of serum tumor markers and immunity function index,clinical efficacy and adverse reactions were compared between the two groups.Result After treatment,the levels of carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),and serum carcinoembryonic antigen(CEA)of the two groups were significantly lower than those before treatment within the same group,and the levels in the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.01).After treatment,the levels of functional indicators CD3^(+),CD4^(+),and CD8^(+) were significantly lower than those before treatment with the same group,and the levels in the observation group were significantly higher than those in the control group the differences werestatistically significant(P<0.01).The treatment control rate of the observation group was 92.50%(37/40)significantly higher than that of the control group 72.50%(29/40)the differences werestatistically significant(χ^(2)=5.541,P=0.019).There was no statistical difference for the incidence of adverse reactions between the two groups(P>0.05).Conclusion Bevacizumab combined chemotherapy in the treatment of advanced lung cancer can effectively reduce the level of serum tumor markers,inhibit disease progression and the impact of chemotherapy on the immunity function,improve the clinical effect,and have high application value.
作者
李金燕
吕伯乐
吕姗
方学辉
LI Jinyan;LYU Bole;LYU Shan;FANG Xuehui(Department of Medical Oncology,Luoyang Dongfang Hospital,Luoyang 471003,He’nan,China)
出处
《癌症进展》
2021年第18期1896-1899,共4页
Oncology Progress
